Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Pharma Mar SAU (PHMMF) - Total Assets
Latest total assets as of September 2025: $342.30 Million USD
Based on the latest financial reports, Pharma Mar SAU (PHMMF) holds total assets worth $342.30 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharma Mar SAU - Total Assets Trend (2002–2024)
This chart illustrates how Pharma Mar SAU’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharma Mar SAU - Asset Composition Analysis
Current Asset Composition (December 2024)
Pharma Mar SAU's total assets of $342.30 Million consist of 71.6% current assets and 28.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.1% |
| Accounts Receivable | $34.68 Million | 9.9% |
| Inventory | $50.89 Million | 14.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.00 Million | 0.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how Pharma Mar SAU's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharma Mar SAU's current assets represent 71.6% of total assets in 2024, an increase from 62.6% in 2002.
- Cash Position: Cash and equivalents constituted 18.1% of total assets in 2024, down from 51.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 14.6% of total assets.
Pharma Mar SAU Competitors by Total Assets
Key competitors of Pharma Mar SAU based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pharma Mar SAU - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Pharma Mar SAU generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Pharma Mar SAU generates $7.47 in net profit.
Pharma Mar SAU - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.73 | 2.66 | 2.59 |
| Quick Ratio | 2.14 | 2.13 | 2.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $154.24 Million | $ 148.58 Million | $ 150.73 Million |
Pharma Mar SAU - Advanced Valuation Insights
This section examines the relationship between Pharma Mar SAU's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.46 |
| Latest Market Cap to Assets Ratio | 3.40 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | $349.64 Million |
| Market Capitalization | $1.19 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Pharma Mar SAU's assets at a significant premium ( 3.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Pharma Mar SAU's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Pharma Mar SAU (2002–2024)
The table below shows the annual total assets of Pharma Mar SAU from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $349.64 Million | +2.68% |
| 2023-12-31 | $340.52 Million | -13.41% |
| 2022-12-31 | $393.26 Million | +6.75% |
| 2021-12-31 | $368.39 Million | +11.54% |
| 2020-12-31 | $330.26 Million | +164.83% |
| 2019-12-31 | $124.70 Million | -20.91% |
| 2018-12-31 | $157.68 Million | -16.00% |
| 2017-12-31 | $187.72 Million | -15.11% |
| 2016-12-31 | $221.14 Million | +4.34% |
| 2015-12-31 | $211.94 Million | +5.24% |
| 2014-12-31 | $201.39 Million | +6.35% |
| 2013-12-31 | $189.37 Million | -5.23% |
| 2012-12-31 | $199.83 Million | -8.26% |
| 2011-12-31 | $217.82 Million | -5.64% |
| 2010-12-31 | $230.82 Million | +9.23% |
| 2009-12-31 | $211.31 Million | +1.82% |
| 2008-12-31 | $207.54 Million | -10.67% |
| 2007-12-31 | $232.33 Million | +3.53% |
| 2006-12-31 | $224.41 Million | -43.00% |
| 2005-12-31 | $393.72 Million | +16.71% |
| 2004-12-31 | $337.34 Million | +22.46% |
| 2003-12-31 | $275.47 Million | +1.49% |
| 2002-12-31 | $271.43 Million | -- |